Tg Drug Patent Portfolio
Tg owns 1 orange book drug protected by 8 US patents Given below is the list of Tg's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414773 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | 26 May, 2035 | Active |
| US10947244 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | 26 May, 2035 | Active |
| US9969740 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | 26 May, 2035 | Active |
| US10072013 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US10570142 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US10981919 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US9150579 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US9669033 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
Latest Legal Activities on Tg's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tg.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 05 Jan, 2026 | US9969740 |
| Notice of Final Determination -Election Required | 06 Nov, 2025 | US10570142 |
| Notice of Final Determination -Election Required | 06 Nov, 2025 | US10072013 |
| Notice of Final Determination -Election Required | 06 Nov, 2025 | US9150579 |
| Notice of Final Determination -Election Required | 06 Nov, 2025 | US9669033 |
| Expire Patent | 14 Jul, 2025 | US9669033 |
| Expire Patent | 26 May, 2025 | US10981919 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US10570142 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9150579 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US9669033 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US10072013 |
| FDA Final Eligibility Letter | 20 May, 2025 | US10072013 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US9150579 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9669033 |
| FDA Final Eligibility Letter | 20 May, 2025 | US10570142 |
Tg's Family Patents
Tg drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 15.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Clinical Trials
Recent Clinical Trials by Tg:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Hydrochloroquinine & Decitabine With Venetoclax in AML | Rutgers, The State University of New Jersey | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes | Jawaharlal Institute of Postgraduate Medical Education & Research | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Opioid Analgesic Reduction Study | Rutgers, The State University of New Jersey | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy | Rutgers, The State University of New Jersey | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients | Rutgers, The State University of New Jersey | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | Rutgers, The State University of New Jersey | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED) | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| The Effect of Sulfasalazine on CRH Levels in Pregnant Women | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| COMMETS- Combination MCI Metabolic Syndrome | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| RADA16 for Adult Tonsillectomy | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study of BGM0504 in Early T2DM With Obesity | BrightGene Bio-Medical Technology Co., Ltd. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Reducing Opioid Use and Misuse After Wisdom Molar Extractions | Rutgers, The State University of New Jersey | NA |
SUSPENDED
(Jun 1, 2026)
| PHASE2 |
| Twin Block, Pain Medications and Third Molar Extractions | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Jaw Muscle Pain Post Wisdom Molar Surgery | Rutgers, The State University of New Jersey | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Study to Evaluate the Safety of Colchicine | Rutgers, The State University of New Jersey | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |
| SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma | Rutgers, The State University of New Jersey | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| Tirzepatide in the Treatment of Endometrial Cancer | Rutgers, The State University of New Jersey | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE2 |
| Microbiome Derived Metabolism and Pharmacokinetics | Rutgers, The State University of New Jersey | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| ATATcH Alternating Treatment Plans for Advanced Cancer | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice | Rutgers, The State University of New Jersey | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |
Tg Drug List
Given below is the complete list of Tg's drugs and the patents protecting them.
1. Ukoniq
Ukoniq is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414773 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
26 May, 2035
(8 years from now)
| Active |
| US10947244 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
26 May, 2035
(8 years from now)
| Active |
| US9969740 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
26 May, 2035
(8 years from now)
| Active |
| US10072013 | Selective PI3K delta inhibitors |
02 Jul, 2033
(6 years from now)
| Active |
| US10570142 | Selective PI3K delta inhibitors |
02 Jul, 2033
(6 years from now)
| Active |
| US10981919 | Selective PI3K delta inhibitors |
02 Jul, 2033
(6 years from now)
| Active |
| US9150579 | Selective PI3K delta inhibitors |
02 Jul, 2033
(6 years from now)
| Active |
| US9669033 | Selective PI3K delta inhibitors |
02 Jul, 2033
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ukoniq's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List